Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The US public health insurance plan - a bridge too far?

This article was originally published in Scrip

Executive Summary

US healthcare reform has edged a little closer after the Senate voted to go ahead and debate its own consolidated reform bill. But it is looking increasingly likely that one of the central proposals – the controversial government-run public health insurance scheme – may have to be jettisoned, or at least heavily diluted, if the reform is to pass Congress.

You may also be interested in...



EMA Pushes For More EU Support For COVID-19 Vaccine Work

Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

EU Politicians: 'Bring Pharma Manufacturing Back To Europe'

The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation. 

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel